OBJECTIVE: More and more highly treatment-experienced patients are achieving viral suppression. However, the durability of suppression remains unclear. METHODS: Patients from Royal Free Hospital (London, UK) and JW Goethe University Hospital (Frankfurt, Germany) who had failed > or = 1 antiretroviral (ARV) regimen in all three main drug classes and > or = 3 previous ARV regimens and subsequently achieved viral load < 50 HIV-1 RNA copies/mL were included. They were followed until stopping pre-combination antiretroviral therapy, end of follow-up or viral rebound (two viral loads >400 copies/mL). RESULTS: Two hundred and forty-seven patients contributed 723 person-years and 114 viral rebounds [rate=15.8 per 100 person-years; 95% confidence interval (CI) 12.9-18.7]. More recent calendar years of viral suppression [relative risk (RR)=0.90 per year later; 95% CI 0.81-1.00; P=0.05] and greater number of ARVs in the regimen not previously failed (RR=0.78 per 1 ARV more; 95% CI 0.65-0.95; P=0.01) were associated with lower viral rebound rates. At 0-1, 1-2, 2-3 and > 3 years after achieving suppression, the rebound rates were 30.9, 9.2, 4.3 and 3.5 per 100 person-years, respectively. Compared to 0-1 years, the adjusted RRs (95% CIs) after 1-2, 2-3 and > 3 years were 0.33 (0.18-0.58), 0.21 (0.09-0.48) and 0.14 (0.06-0.33), respectively (P<0.0001). CONCLUSIONS: Although rebound rates are high, especially in the first year after viral suppression, this risk reduces substantially if highly treatment-experienced patients can maintain viral suppression.
OBJECTIVE: More and more highly treatment-experienced patients are achieving viral suppression. However, the durability of suppression remains unclear. METHODS:Patients from Royal Free Hospital (London, UK) and JW Goethe University Hospital (Frankfurt, Germany) who had failed > or = 1 antiretroviral (ARV) regimen in all three main drug classes and > or = 3 previous ARV regimens and subsequently achieved viral load < 50 HIV-1 RNA copies/mL were included. They were followed until stopping pre-combination antiretroviral therapy, end of follow-up or viral rebound (two viral loads >400 copies/mL). RESULTS: Two hundred and forty-seven patients contributed 723 person-years and 114 viral rebounds [rate=15.8 per 100 person-years; 95% confidence interval (CI) 12.9-18.7]. More recent calendar years of viral suppression [relative risk (RR)=0.90 per year later; 95% CI 0.81-1.00; P=0.05] and greater number of ARVs in the regimen not previously failed (RR=0.78 per 1 ARV more; 95% CI 0.65-0.95; P=0.01) were associated with lower viral rebound rates. At 0-1, 1-2, 2-3 and > 3 years after achieving suppression, the rebound rates were 30.9, 9.2, 4.3 and 3.5 per 100 person-years, respectively. Compared to 0-1 years, the adjusted RRs (95% CIs) after 1-2, 2-3 and > 3 years were 0.33 (0.18-0.58), 0.21 (0.09-0.48) and 0.14 (0.06-0.33), respectively (P<0.0001). CONCLUSIONS: Although rebound rates are high, especially in the first year after viral suppression, this risk reduces substantially if highly treatment-experienced patients can maintain viral suppression.
Authors: M-J Milloy; Thomas Kerr; Jane Buxton; Tim Rhodes; Andrea Krusi; Silvia Guillemi; Robert Hogg; Julio Montaner; Evan Wood Journal: J Acquir Immune Defic Syndr Date: 2012-04-01 Impact factor: 3.731
Authors: David B Hanna; Uriel R Felsen; Mindy S Ginsberg; Barry S Zingman; Robert S Beil; Donna C Futterman; Howard D Strickler; Kathryn Anastos Journal: AIDS Res Hum Retroviruses Date: 2016-03-17 Impact factor: 2.205
Authors: Stephen Opoku; Samuel Asamoah Sakyi; Nana Kwame Ayisi-Boateng; Anthony Kwame Enimil; Ebenezer Senu; Richard Owusu Ansah; Bismark Dankwah Aning; Diana Atsieno Ojuang; Doreen Nafula Wekesa; Fatima Osman Ahmed; Chidinma B Okeke; Ama Darkoaa Sarfo Journal: AIDS Res Ther Date: 2022-05-25 Impact factor: 2.846
Authors: Rebecca Lodwick; Dominique Costagliola; Peter Reiss; Carlo Torti; Ramón Teira; Maria Dorrucci; Bruno Ledergerber; Amanda Mocroft; Daniel Podzamczer; Alessandro Cozzi-Lepri; Niels Obel; Bernard Masquelier; Schlomo Staszewski; Federico García; Stephane De Wit; Antonella Castagna; Andrea Antinori; Ali Judd; Jade Ghosn; Giota Touloumi; Cristina Mussini; Xavier Duval; José Ramos; Laurence Meyer; Josiane Warsawski; Claire Thorne; Joan Masip; Santiago Pérez-Hoyos; Deenan Pillay; Ard van Sighem; Sergio Lo Caputo; Huldrych Günthard; Roger Paredes; Andrea De Luca; Dimitrios Paraskevis; Céline Fabre-Colin; Jesper Kjaer; Genèvieve Chêne; Jens D Lundgren; Andrew N Phillips Journal: Arch Intern Med Date: 2010-03-08
Authors: Debra A Benator; Angelo Elmi; Manuel D Rodriguez; Howard B Gale; Virginia L Kan; Heather J Hoffman; Susan Tramazzo; Karen Hall; Angela McKnight; Leah Squires Journal: AIDS Behav Date: 2015-04
Authors: Alexander O Pasternak; Suzanne Jurriaans; Margreet Bakker; Jan M Prins; Ben Berkhout; Vladimir V Lukashov Journal: PLoS One Date: 2009-12-31 Impact factor: 3.240